Antidote is a digital health company on a mission to accelerate medical research. In a world where 80% of clinical trials are delayed or closed due to a shortage of suitable participants, Antidote uses precision recruitment to match the right patients with the right trials, striking the right balance between technology and human touch to deliver high-quality patient engagement. This is achieved through the integration of data-driven technologies, digital expertise, deep domain experience, an extensive diverse partner network, and personalized patient and site services. Antidote was launched as TrialReach and is based in the US and UK.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/03/21 | $23,200,000 | Venture |
LBO France Merck Global Health Innovation Fund Octopus Ventures Smedvig Capital | undisclosed |
